Technical Analysis for CYCN - Cyclerion Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Volume Surge | Other | 6.98% | |
| Calm After Storm | Range Contraction | 6.98% | |
| NR7 | Range Contraction | 6.98% |
| Alert | Time |
|---|---|
| Gapped Down (Partial) | about 10 hours ago |
| Down 5% | about 10 hours ago |
| Down 3% | about 10 hours ago |
| Down 2 % | about 10 hours ago |
| Down 1% | about 10 hours ago |
Get a Trading Assistant
- Earnings date: 07/26/2024
Cyclerion Therapeutics, Inc. Description
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its current portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Disease Organ Systems Pharmacology Kidney Disease Heart Failure Diabetic Nephropathy Cardiomyopathy Central Nervous System Disease Orphan Disease Sickle Cell Disease Lung Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Date | Title |
|---|---|
| Mar 24 | 12 Best Biotech Penny Stocks to Invest In |
| Indicator | Value |
|---|---|
| 52 Week High | 5.25 |
| 52 Week Low | 1.7501 |
| Average Volume | 3,517 |
| 200-Day Moving Average | 3.02 |
| 50-Day Moving Average | 2.75 |
| 20-Day Moving Average | 2.49 |
| 10-Day Moving Average | 2.48 |
| Average True Range | 0.36 |
| RSI (14) | 44.13 |
| ADX | 14.97 |
| +DI | 20.16 |
| -DI | 28.26 |
| Chandelier Exit (Long, 3 ATRs) | 2.02 |
| Chandelier Exit (Short, 3 ATRs) | 2.97 |
| Upper Bollinger Bands | 2.98 |
| Lower Bollinger Band | 2.00 |
| Percent B (%b) | 0.3 |
| BandWidth | 39.28 |
| MACD Line | -0.11 |
| MACD Signal Line | -0.10 |
| MACD Histogram | -0.0083 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.69 | ||||
| Resistance 3 (R3) | 2.65 | 2.47 | 2.63 | ||
| Resistance 2 (R2) | 2.47 | 2.37 | 2.50 | 2.60 | |
| Resistance 1 (R1) | 2.39 | 2.31 | 2.43 | 2.43 | 2.58 |
| Pivot Point | 2.21 | 2.21 | 2.24 | 2.24 | 2.21 |
| Support 1 (S1) | 2.13 | 2.11 | 2.17 | 2.17 | 2.02 |
| Support 2 (S2) | 1.95 | 2.05 | 1.98 | 2.00 | |
| Support 3 (S3) | 1.87 | 1.95 | 1.98 | ||
| Support 4 (S4) | 1.91 |
